Medincell to Present at the 2024 Jefferies Global Healthcare Conference, June 4 to 6, 2024, New York
21 Mayo 2024 - 11:00AM
Business Wire
Regulatory News:
Medincell (Paris:MEDCL):
Christophe Douat, CEO, and Richard Malamut, CMO, will present
Medincell's portfolio and R&D pipeline at the Jefferies Global
Healthcare Conference on June 6 at 1:00pm ET (19h00 CEST) at the
Marriott Marquis Hotel in New York City
Investors can access the presentation remotely, either live
or on replay, following this link:
https://wsw.com/webcast/jeff302/mebgr/1977936
1X1 meetings with the management team may be arranged by
directly contacting MedinCell:
grace.kim@medincell.com
“Our American strategy initiated last summer is already paying
off. Top US investors, who have fully understood Medincell's short-
and long-term potential, are on board. They are essential partners
of our accelerating growth.”, said Christophe Douat, CEO of
Medincell.
"With the successful launch of Teva-partnered UZEDY® and
positive phase 3 results for mdc-TJK, a potentially first-mover LAI
olanzapine product with no black-box warning for severe
schizophrenia, our well-validated BEPO technology continues to
attract strong alliances including the recently announced major
partnership with AbbVie. With additional early- and late-stage
pipeline programs, encouraging data on Ph3 mdc-CWM, and additional
upcoming catalysts - we look forward to sharing our progress and
plans with fundamental investors," said Grace Kim, Medincell Head
of US Financial Strategy.
Medincell has recently reached the commercial stage with the
market launch by Teva of UZEDY® for the treatment of schizophrenia.
UZEDY is the first innovative product based on Medincell’s
long-acting injectable (LAI) BEPO® technology approved by US
FDA.
Teva has recently confirmed the annual revenue guidance for
UZEDY, projecting approximately $80 million for 2024. This revenue
estimate is in line with Medincell's anticipated earnings from
UZEDY, as the company is set to receive royalties from sales and
could earn up to $105 million in commercial milestones.
In parallel, Medincell is developing a portfolio of innovative
treatments also using the BEPO technology. This notably includes
the following candidate treatments:
2 candidates in clinical Phase 3:
- mdc-TJK (in partnership with Teva): potentially, the first
long-acting injectable olanzapine with a favorable safety profile
that could enable a large adoption for treatment of patients with
more severe forms of schizophrenia. Positive efficacy results have
recently been announced. (press release)
- mdc-CWM (in partnership with AIC): an innovative
sustained-release formulation of a non-steroidal anti-inflammatory
drug celecoxib aiming at facilitating patient recovery after total
knee replacement and decreasing the need for potentially addictive
opioids. The encouraging results of the first phase 3 presented
recently have paved the way for the next stages of regulatory
development. (press release)
2 candidates in preclinical stage:
- mdc-WWM: 6-month active subcutaneous contraceptive
- mdc-STM: Global Health program to fight malaria
10 programs in formulation stage:
- Among them, the first program selected with AbbVie as part of a
strategic co-development and licensing agreement, recently
announced (press release), to develop next-generation of
long-acting injectable therapies. Medincell and AbbVie will
co-develop up to six innovative long-acting injectable products and
AbbVie will responsible their commercialization. Medincell received
the upfront payment of $35 million and is eligible to receive up to
$1.9 billion in development and commercial milestones, as well as
royalties on worldwide sales.
About Medincell
Medincell is a clinical- and commercial-stage biopharmaceutical
licensing company developing long-acting injectable drugs in many
therapeutic areas. Our innovative treatments aim to guarantee
compliance with medical prescriptions, to improve the effectiveness
and accessibility of medicines, and to reduce their environmental
footprint. They combine active pharmaceutical ingredients with our
proprietary BEPO® technology which controls the delivery of a drug
at a therapeutic level for several days, weeks or months from the
subcutaneous or local injection of a simple deposit of a few
millimeters, entirely bioresorbable. The first treatment based on
BEPO® technology, intended for the treatment of schizophrenia, was
approved by the FDA in April 2023, and is now distributed in the
United States by Teva under the name UZEDY® (BEPO® technology is
licensed to Teva under the name SteadyTeq™). We collaborate with
leading pharmaceutical companies and foundations to improve global
health through new treatment options. Based in Montpellier,
Medincell currently employs more than 140 people representing more
than 25 different nationalities.
UZEDY® and SteadyTeq™ are trademarks of Teva Pharmaceuticals
www.Medincell.com
This press release contains forward-looking statements,
including statements regarding Company’s expectations for (i) the
timing, progress and outcome of its clinical trials; (ii) the
clinical benefits and competitive positioning of its product
candidates; (iii) its ability to obtain regulatory approvals,
commence commercial production and achieve market penetration and
sales; (iv) its future product portfolio; (v) its future partnering
arrangements; (vi) its future capital needs, capital expenditure
plans and ability to obtain funding; and (vii) prospective
financial matters regarding our business. Although the Company
believes that its expectations are based on reasonable assumptions,
any statements other than statements of historical facts that may
be contained in this press release relating to future events are
forward-looking statements and subject to change without notice,
factors beyond the Company's control and the Company's financial
capabilities.
These statements may include, but are not limited to, any
statement beginning with, followed by or including words or phrases
such as "objective", "believe", "anticipate", “expect”, "foresee",
"aim", "intend", "may", "anticipate", "estimate", "plan",
"project", "will", "may", "probably", “potential”, "should",
"could" and other words and phrases of the same meaning or used in
negative form. Forward-looking statements are subject to inherent
risks and uncertainties beyond the Company's control that may, if
any, cause actual results, performance, or achievements to differ
materially from those anticipated or expressed explicitly or
implicitly by such forward-looking statements. A list and
description of these risks, contingencies and uncertainties can be
found in the documents filed by the Company with the Autorité des
Marchés Financiers (the "AMF") pursuant to its regulatory
obligations, including the Company's registration document,
registered with the AMF on September 4, 2018, under number I.
18-062 (the "Registration Document"), as well as in the documents
and reports to be published subsequently by the Company. In
particular, readers' attention is drawn to the section entitled
"Facteurs de Risques" on page 26 of the Registration Document.
Any forward-looking statements made by or on behalf of the
Company speak only as of the date they are made. Except as required
by law, the Company does not undertake any obligation to publicly
update these forward-looking statements or to update the reasons
why actual results could differ materially from those anticipated
by the forward-looking statements, including in the event that new
information becomes available. The Company's update of one or more
forward-looking statements does not imply that the Company will
make any further updates to such forward-looking statements or
other forward-looking statements. Readers are cautioned not to
place undue reliance on these forward-looking statements.
This press release is for information purposes only. The
information contained herein does not constitute an offer to sell
or a solicitation of an offer to buy or subscribe for the Company's
shares in any jurisdiction, in particular in France. Similarly,
this press release does not constitute investment advice and should
not be treated as such. It is not related to the investment
objectives, financial situation, or specific needs of any
recipient. It should not deprive the recipients of the opportunity
to exercise their own judgment. All opinions expressed in this
document are subject to change without notice. The distribution of
this press release may be subject to legal restrictions in certain
jurisdictions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240521325398/en/
David Heuzé Head of Corporate and Financial
Communications, and ESG david.heuze@MedinCell.com / +33 (0)6 83 25
21 86
Grace Kim Head of US Financial Strategy & IR
grace.kim@MedinCell.com / +1 (646) 991-4023
Nicolas Mérigeau/ Arthur Rouillé Media Relations
Medincell@newcap.eu / +33 (0)1 44 71 94 94
Louis-Victor Delouvrier/Alban Dufumier Investor Relations
France Medincell@newcap.eu / +33 (0)1 44 71 94 94
Medincell (EU:MEDCL)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Medincell (EU:MEDCL)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024